Major study tests pneumonia vaccine shield for HIV community
NCT ID NCT05794191
Summary
This study looked at how well the Prevnar 13 (PCV13) vaccine works to prevent pneumonia in adults living with HIV. Researchers analyzed the health records of over 350,000 people to compare rates of pneumonia between those who received the vaccine and those who did not. The goal was to understand the vaccine's real-world effectiveness in protecting this higher-risk group from serious bacterial infections.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Pfizer
New York, New York, 10001, United States
Conditions
Explore the condition pages connected to this study.